Oncology Beyond COVID-19

article image

Cancer care’s unique dynamics during the COVID-19 pandemic have affected medical device and diagnostics companies in multiple ways. A decline in routine screening has hurt follow-up care, but some innovative devices that treat the most aggressive cancers are booming. We look at the pandemic’s impact on Novocure and Veracyte.

Cancer care is not elective, but even it has been impacted by the COVID-19 lockdown, particularly by reduced demand for diagnostic and screening workups that are necessary precursors of treatment and, also, by restricted access to hospitals. Hoped-for efforts to catch up are anticipated for later this year as society re-opens but will not completely offset the absolute losses in procedure volume. Delays in initiation into therapy and clinical trial enrollment are likely to have long-term health ramifications—although those may not be apparent for some time.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: